Related Experiment Videos
Treating mixed dyslipidemias: why and how
1Section of Atherosclerosis, Baylor College of Medicine, Houston, Texas 77030, USA. cmb@bcm.tmc.edu
Insights
Patients with low HDL-C and high triglycerides face high cardiovascular risk. Statins and fibrates show potential benefits, with combination therapy improving lipid profiles but raising concerns about cost and side effects.
Area of Science:
- Cardiology
- Metabolic Disorders
- Pharmacology
Background:
- Patients with mildly elevated low-density lipoprotein cholesterol (LDL-C) but low high-density lipoprotein cholesterol (HDL-C) and/or high triglycerides are at increased risk for cardiovascular disease (CVD).
- Dyslipidemia, characterized by abnormal lipid levels, is a significant risk factor for atherosclerosis and related cardiovascular events.
Purpose of the Study:
- To review the efficacy of lipid-lowering therapies, including statins, fibrates, and combination treatments, in managing dyslipidemia and reducing cardiovascular risk.
- To evaluate the impact of these therapies on low high-density lipoprotein cholesterol (HDL-C) and triglyceride levels in at-risk patients.
Main Methods:
- Literature review of clinical trials and studies investigating the effects of statins, fibrates, and combination therapies on lipid profiles and cardiovascular outcomes.
- Analysis of data concerning patients with mixed dyslipidemias, specifically focusing on low HDL-C and elevated triglycerides.
Main Results:
- Statins have demonstrated effectiveness in slowing coronary heart disease (CHD) progression and reducing CHD events, particularly in patients with low HDL-C.
- Fibrate trials have yielded mixed results regarding their benefit in patients with low HDL-C.
- Combination therapy with statins and fibrates or niacin effectively improves the overall lipid profile, including HDL-C and triglycerides.
Conclusions:
- Statins are beneficial for patients with low HDL-C and mixed dyslipidemias.
- Combination therapy offers comprehensive lipid profile improvement but necessitates consideration of increased costs and potential side effects.
- Further research may be warranted to optimize combination therapy strategies for cardiovascular risk reduction.
Abstract:
Patients with only mildly elevated low-density lipoprotein cholesterol values but low high-density lipoprotein cholesterol (HDL-C) and/or high triglyceride levels are at high risk for cardiovascular disease. 3-Hydroxy-3-methyl-glutaryl-coenzyme A reductase inhibitors (also known as statins) have been shown to slow coronary heart disease (CHD) progression, reduce CHD events in patients with low HDL-C levels, and raise HDL-C concentrations in patients with mixed dyslipidemias. Some, but not all trials of fibrates have shown benefit in patients with low HDL-C levels. Combination therapy with a statin plus either a fibrate or niacin is effective in improving the entire lipid profile, but may increase cost and side effects.